Mesothelioma.com Resources for Patients and their Families

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Brief Summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Tracking Information
First Received DateOctober 28, 2015
Last Changed DateMay 29, 2016
Start DateOctober 2015
Actual Primary Completion DateMay 2016
Primary Outcome Measures

to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival [Time Frame: 3-4 months]

Secondary Outcome Measures

assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74 [Time Frame: 3-4 months]

Descriptive Information
PhaseN/A
Study TypeObservational
Condition
  • Malignant Pleural Mesotheliomas
Intervention
  • Other: marker CD74 and vascular endothelial growth factor VEGF
Study Arms / Comparison Groups0 / 1
Detailed Description

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment50
GenderAll
Ages39 Years - 84 Years
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Histopathological confirmation of malignant pleural mesothelioma .

- Full clinical data.

- Availability for follow up: Personal communication will be attempted in order to collect missing information.

3-The files of all patients will be reviewed to analyze the following :

- Operative data if done .

- Pathological review and immunohistochemistry.

- Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)

- Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).

- Treatment protocols applied: Radiotherapy and Chemotherapy.

- Response and survival after treatment .

Exclusion Criteria:

- cases not receive chemotherapy ,on available of evaluation after treatment

Administrative Information
NCTIDNCT02603315
Responsible Party,
SponsorAin Shams University
Verification DateOctober 2015
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

High Cost of Asbestos Abatement Leaves Lower Income Communities at Risk

Staying Safe from Asbestos After Natural Disasters

Steve McQueen and Mesothelioma: An Actor and Veteran’s Last Battle

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: